Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply

Nina Løn, Sara Engel, Anders Damholt, Anja Wellejus, Filip K. Knop*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftLederForskningpeer review

1 Citationer (Scopus)
4 Downloads (Pure)

Abstract

We thank Dr. Taha for his editorial on our article.1, 2 As discussed by Dr. Taha in a recent article for the British Society of Gastroenterology, the risk of NSAID-induced gastrointestinal damage should be addressed during long-term NSAID treatment, and we compliment Dr. Taha for emphasising the potential of a safe dietary supplement such as the probiotic strain Bifidobacterium breve Bif195 (DSM 33360), for aspirin users.3 We agree that alternative treatment strategies that may enable safe continuous NSAID treatment are warranted.
OriginalsprogEngelsk
TidsskriftAlimentary Pharmacology and Therapeutics
Vol/bind59
Udgave nummer4
Sider (fra-til)577-578
Antal sider2
ISSN0269-2813
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The author's declaration of personal and funding interests are unchanged from those in the original article.2

Citationsformater